You are here
Treat-to-target (T2T) strategy is widely advocated as an important means of optimizing treatment responses in patients with rheumatoid arthritis (RA). Even though T2T is encouraged by most guidelines, a current report shows that US Rheumatologists fail to implement T2T in their daily practice.
Rheumatology researchers from the Brigham and Women's Hospital have published the results of the TRACTION trial, which was a randomized controlled study of 641 RA patients recruited from 46 providers practicing at 11 US sites. They collected data on implementation of T2T, patient covariates, provider characteristics, site variables and also calculated a “T2T implementation score” as the percentage of features recorded.
Specifically they were seeking to identify four components of T2T from the medical records. These included:
- A disease activity target “treatment target”
- A RA disease activity measure, recommended by the ACR (CDAI, SDAI, DAS28, PAS, PASII, RAPID3)
- Documented shared-decision making
- Treatment decisions based on target and disease activity measures
Overall T2T Implementation was sub-optimal: nearly two-thirds (64%) of RA patients visits having none of the T2T components recorded, 33.1% had one component, 2.3% had two components, and 0.3% had all components.
T2T implementation differed significantly across providers and sites (P-values < 0.0001).
Older rheumatolgoists with longer experience had higher implementation score; while younger rheumatologists (fellows) had lower T2T scores.
These findings are sobering. Curtis et al have recently shown that over half of rheumatologists collect some measure, but theres little evidence that it affects decision making or therapeutics (J Rheum, http://bit.ly/2IuXWLE). Hence, while most rheumatologists believe they practice T2T (largely because they measure something), there is little proof that they manage and treat using well defined T2T strategies.